Abstract
Development of drug resistance to anticancer drugs is an important challenge for cancer treatment. Recent studies focus on co-delivery of anticancer drugs and siRNA to overcome this challenge. Mesoporous silica nanoparticles (MSNs) are one of the promising nanoparticles that enable the delivery of drugs and siRNA simultaneously. MSNs coated with copolymer capable of co-delivery of drug and siRNA were prepared and characterized. In the present study, MSNs functionalized with polyethylenimine-polyethylene glycol (PEI-PEG) copolymer were prepared. MSNs were characterized using dynamic light scattering (DLS), Transmission Electron Microscopy (TEM) and elemental analysis. Nanoparticles were loaded with epirubicin hydrochloride (EPI) and anti B-cell lymphoma 2 (BCL-2) siRNA. The in vitro cytotoxicity and in vivo efficacy of different formulations were evaluated. Mean size of MSNs ranged from 98 to 247 nm. EPI release from MSNs was pH-dependent. MSNs loaded with EPI and siRNA showed better in vitro cytotoxicity with 1 μg/mL EPI and 50-400 ng/mL siRNA, besides MSNs loaded with 9 mg/kg EPI and 1.2 mg/kg siRNA resulted in improved in vivo effects compared to EPI or MSNs containing EPI or siRNA alone. The results of in vitro and in vivo studies indicated the synergistic effect of EPI and anti BCL-2 siRNA. This formulation could be a promising nanoparticle for codelivery of drug and siRNA in cancer cells.
Keywords: BCL-2, Cancer treatment, Co-delivery, Epirubicin, Mesoporous silica nanoparticles, siRNA.
Current Drug Delivery
Title:Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy
Volume: 13 Issue: 7
Author(s): Mohammad Yahya Hanafi-Bojd, Mahmoud Reza Jaafari, Navid Ramezanian, Khalil Abnous and Bizhan Malaekeh-Nikouei
Affiliation:
Keywords: BCL-2, Cancer treatment, Co-delivery, Epirubicin, Mesoporous silica nanoparticles, siRNA.
Abstract: Development of drug resistance to anticancer drugs is an important challenge for cancer treatment. Recent studies focus on co-delivery of anticancer drugs and siRNA to overcome this challenge. Mesoporous silica nanoparticles (MSNs) are one of the promising nanoparticles that enable the delivery of drugs and siRNA simultaneously. MSNs coated with copolymer capable of co-delivery of drug and siRNA were prepared and characterized. In the present study, MSNs functionalized with polyethylenimine-polyethylene glycol (PEI-PEG) copolymer were prepared. MSNs were characterized using dynamic light scattering (DLS), Transmission Electron Microscopy (TEM) and elemental analysis. Nanoparticles were loaded with epirubicin hydrochloride (EPI) and anti B-cell lymphoma 2 (BCL-2) siRNA. The in vitro cytotoxicity and in vivo efficacy of different formulations were evaluated. Mean size of MSNs ranged from 98 to 247 nm. EPI release from MSNs was pH-dependent. MSNs loaded with EPI and siRNA showed better in vitro cytotoxicity with 1 μg/mL EPI and 50-400 ng/mL siRNA, besides MSNs loaded with 9 mg/kg EPI and 1.2 mg/kg siRNA resulted in improved in vivo effects compared to EPI or MSNs containing EPI or siRNA alone. The results of in vitro and in vivo studies indicated the synergistic effect of EPI and anti BCL-2 siRNA. This formulation could be a promising nanoparticle for codelivery of drug and siRNA in cancer cells.
Export Options
About this article
Cite this article as:
Hanafi-Bojd Yahya Mohammad, Jaafari Reza Mahmoud, Ramezanian Navid, Abnous Khalil and Malaekeh-Nikouei Bizhan, Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy, Current Drug Delivery 2016; 13 (7) . https://dx.doi.org/10.2174/1567201813666151231094056
DOI https://dx.doi.org/10.2174/1567201813666151231094056 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Update on Eosinophilic Lung Diseases and Anti-IL-5 Treatment
Recent Patents on Anti-Infective Drug Discovery Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design A Descriptive Analysis of Post-Chemotherapy Development of Interstitial Lung Disease Using Spontaneous Reporting Data in Japan
Current Drug Safety Plant Cells as Pharmaceutical Factories
Current Pharmaceutical Design Advances and Challenges in the Synthesis of Highly Oxidised Natural Phenols with Antiviral, Antioxidant and Cytotoxic Activities
Current Medicinal Chemistry 2-Arylbenzimidazoles as Antiviral and Antiproliferative Agents-Part 2
Medicinal Chemistry Bladder Cancer: A Simple Model Becomes Complex
Current Genomics Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Distinctive Cellular Roles for Novel Protein Kinase C Isoenzymes
Current Pharmaceutical Design Dendritic Cell Immunotherapy for Malignant Gliomas
Reviews on Recent Clinical Trials Isoform-Selective PI3K Inhibitors for Various Diseases
Current Topics in Medicinal Chemistry Marine Metabolites Overcoming or Circumventing Multidrug Resistance Mediated by ATP-Dependent Transporters: A New Hope for Patient with Tumors Resistant to Conventional Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Bioinformatic Tools Identify Chromosome-Specific DNA Probes and Facilitate Risk Assessment by Detecting Aneusomies in Extra-embryonic Tissues
Current Genomics Chemical Genomic and Proteomic Methods for Determining Kinase Inhibitor Selectivity
Combinatorial Chemistry & High Throughput Screening Chemotherapeutic Effects of Acridine Derivatives
Medicinal Chemistry Reviews - Online (Discontinued) Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies Gene Polymorphisms and Pharmacogenetics in Rheumatoid Arthritis
Current Genomics A Review on PARP1 Inhibitors: Pharmacophore Modeling, Virtual and Biological Screening Studies to Identify Novel PARP1 Inhibitors
Current Topics in Medicinal Chemistry Modular Branched Neurotensin Peptides for Tumor Target Tracing and Receptor-Mediated Therapy: A Proof-of-Concept
Current Cancer Drug Targets Biologic Therapy in Psoriasis: Safety Profile
Current Drug Safety